Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:43:43 EDT Sat 16 May 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:RVMD - REVOLUTION MEDICINES INC - https://ir.revmed.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVMD - Q0.1120.00·146.030.1145.66-3.81-2.52,475.8356,44523,076147.84  148.855  141.25155.70  34.0019:31:16May 0615 min RT 2¢

Recent Trades - Last 10 of 23076
Time ETExPriceChangeVolume
19:31:16Q145.00-4.475
19:23:03Q145.8285-3.64158
19:23:03Q145.8285-3.64152
17:39:20Q145.00-4.47150
17:18:52Q145.97-3.5010
17:18:52Q145.8285-3.641510
17:18:52Q145.8285-3.641520
17:18:52Q145.97-3.5011
17:18:52Q145.8285-3.641511
17:06:46Q146.03-3.44100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-05-06 18:00U:RVMDNews ReleaseRevolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
2026-05-06 16:02U:RVMDNews ReleaseRevolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
2026-04-29 16:05U:RVMDNews ReleaseRevolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
2026-04-21 17:35U:RVMDNews ReleaseRevolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
2026-04-21 17:30U:RVMDNews ReleaseRevolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
2026-04-21 11:23U:RVMDNews ReleaseRevolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
2026-04-19 14:00U:RVMDNews ReleaseRevolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
2026-04-17 16:02U:RVMDNews ReleaseRevolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
2026-04-15 00:41U:RVMDNews ReleaseRevolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
2026-04-13 16:01U:RVMDNews ReleaseRevolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes
2026-04-13 08:00U:RVMDNews ReleaseDaraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
2026-04-02 08:00U:RVMDNews ReleaseRevolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer
2026-03-17 18:37U:RVMDNews ReleaseRevolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting
2026-02-25 16:02U:RVMDNews ReleaseRevolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
2026-02-24 16:05U:RVMDNews ReleaseRevolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference
2026-02-18 16:05U:RVMDNews ReleaseRevolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026
2026-02-04 16:05U:RVMDNews ReleaseRevolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
2026-01-29 08:00U:RVMDNews ReleaseRevolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
2026-01-08 08:00U:RVMDNews ReleaseRevolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
2026-01-05 16:05U:RVMDNews ReleaseRevolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference